May 11, 2018
Ono Pharmaceutical’s immuno-oncology star Opdivo (nivolumab) saw its sales dwindle 13% to 90.1 billion yen in the year ended March 2018, despite a 45% volume increase, as it took a full-year blow from a 50% emergency price slashed imposed in...read more